Eli Lilly (LLY.N) and Regeneron Pharmaceuticals (REGN.O) have become among the first companies selected for a new pilot program run by the U.S. Food and Drug Administration.
According to Jin10, CNBC reported that the two drugmakers were included in the initial group admitted to the FDA’s new trial initiative.
STOCKS | Eli Lilly and Regeneron Join FDA’s New Pilot Program
2026-06-30 02:57:15
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
